RecruitingNCT06505486

GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC

Studying Cholangiocarcinoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Principal Investigator
Jia-yan Ni, M.D.
Sun Yat-sem Memorial Hospital, Sun Yat-sen University
Intervention
Gemcitabine-Oxaliplatin Regimen(drug)
Enrollment
21 enrolled
Eligibility
18-70 years · All sexes
Timeline
2024 – 2025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06505486 on ClinicalTrials.gov

Other trials for Cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Cholangiocarcinoma →

← Back to all trials